| "Chlorobi" Garrity and Holt 2001| Chlorobaeota| Chlorobaeota Oren et al. 2015| Chlorobi| Chlorobi Iino et al. 2010| Chlorobiota| Green sulfur bacteria
Sulfur metabolism: Chlorobiota bacteria are capable of anoxygenic photosynthesis, using sulfur compounds as electron donors instead of water. This metabolic capability contributes to sulfur cycling in anaerobic environments, where Chlorobiota bacteria participate in the reduction of sulfide and other sulfur compounds. While sulfur cycling is important for ecosystem functioning, alterations in sulfur metabolism could potentially impact water quality parameters and nutrient cycling in aquatic ecosystems, which may indirectly affect human health through changes in ecosystem services or the availability of resources.
Ecological interactions: Chlorobiota bacteria interact with other organisms in anaerobic environments, including other bacteria, archaea, algae, and higher organisms. These ecological interactions influence nutrient cycling, energy flow, and ecosystem dynamics in sediments, wetlands, and aquatic habitats. While the ecological impacts of Chlorobiota are primarily of interest from an environmental perspective, changes in ecosystem functioning could indirectly affect human well-being, such as through alterations in water quality, biodiversity, or the provision of ecosystem services.
Biotechnological applications: Some Chlorobiota bacteria have been studied for their potential biotechnological applications, particularly in environmental or industrial processes such as wastewater treatment, bioremediation, and bioenergy production. While these applications are primarily focused on engineering or ecological objectives rather than direct human health impacts, they highlight the diverse metabolic capabilities and potential practical uses of Chlorobiota bacteria in engineered or managed ecosystems.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 1.24 | 1 | 1140 | 0 | 678 | 176.6 | 70 | 255.7 | 0 | 450 | 0 %ile | 100 %ile | ||
biomesight | 77.16 | 0 | 160 | 30 | 370 | 0 | 1698 | 285.7 | 90 | 720.3 | 0 | 410 | 9 %ile | 90.8 %ile |
thorne | 100 | 15 | 373 | 0 | 224 | 75.2 | 45 | 75.8 | 27 | 107 | 0 %ile | 100 %ile | ||
thryve | 8.12 | 0 | 0 | 1 | 68 | 0 | 47 | 22 | 19 | 12.7 | 7 | 37 | 0 %ile | 100 %ile |
ubiome | 0.13 | 0 | 26 | 26 | 26 | 26 | 26 | 0 %ile | 99 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 32.55 | 68.16 | 0.0033 | 0.0068 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
Biomesight | 82.431 % | 0.027 % | 0.068 % | 2360.0 | 2863 |
BiomeSightRdp | 75 % | 0.019 % | 0.026 % | 24.0 | 32 |
CerbaLab | 66.667 % | 0.001 % | 0 % | 2.0 | 3 |
custom | 8.475 % | 0.001 % | 0.001 % | 5.0 | 59 |
es-xenogene | 13.793 % | 0.032 % | 0.013 % | 4.0 | 29 |
Medivere | 28.571 % | 0.002 % | 0.001 % | 2.0 | 7 |
Thorne | 82.955 % | 0.004 % | 0.006 % | 73.0 | 88 |
Thryve | 7.881 % | 0.002 % | 0.001 % | 109.0 | 1383 |
uBiome | 0.126 % | 0.003 % | % | 1.0 | 792 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.